N,N'-di-tert-butyl-p-phenylenediamine | 42574-83-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N'-di-tert-butyl-p-phenylenediamine
• 英文别名: N,N'-Di-tert-butyl-p-phenylendiamin；1-N,4-N-ditert-butylbenzene-1,4-diamine
• CAS: 42574-83-4
• 化学式: C₁₄H₂₄N₂
• 分子量: 220.358
• InChiKey: CMGXCZJLZPWTGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N'-di-tert-butyl-p-phenylenediamine 生成 N,N'-di-tert-butyl-N,N'-dinitroso-p-phenylenediamine
  参考文献：
  名称：

  Production of n-tertiary alkylated aromatic secondary diamines

  摘要：

  公开号：

  US02692288A1
• 作为产物：
  描述：

  叔丁醇 、 对苯二胺盐酸盐 在 碘 作用下， 生成 N,N'-di-tert-butyl-p-phenylenediamine
  参考文献：
  名称：

  Production of n-tertiary alkylated aromatic secondary diamines

  摘要：

  公开号：

  US02692288A1

文献信息

• CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
  申请人：Sufi Bilal

  公开号：US20100145036A1

  公开（公告）日：2010-06-10

  The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物和药物可切割底物共轭物，它们是有效的细胞毒素。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• COMPOUND, LIQUID COMPOSITION, THERMAL TRANSFER RECORDING SHEET, TONER, RESIST COMPOSITION FOR COLOR FILTER, AND COLOR FILTER
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20200347007A1

  公开（公告）日：2020-11-05

  Provided is, for example, a compound excellent in light fastness and storage stability. The compound is characterized by having a structure represented by the following formula (1) or (2).

  提供的是一种在耐光性和储存稳定性方面表现优异的化合物。该化合物的特征是具有以下公式（1）或（2）所代表的结构。
• Novel antibacterial agents
  申请人：Christensen G. Burton

  公开号：US20070134729A1

  公开（公告）日：2007-06-14

  This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

  本发明涉及一种新型多结合化合物（药剂），其为抗菌剂。该发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个单价（即未连接的）配体具有与细胞壁生物合成和代谢中的酶、合成细菌细胞壁和/或细菌细胞表面的前体有结合能力，从而干扰细胞壁的合成和/或代谢。特别地，本发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个配体具有能够结合青霉素结合蛋白、横向肽酶酶、横向肽酶酶底物、β-内酰胺酶、青霉素酶、头孢菌素酶、横向转移酶酶或横向转移酶酶底物的配体结构域。优选地，配体选自β-内酰胺类或糖肽类抗菌剂。
• Anti-Malarial Compounds
  申请人：Scott Richard W.

  公开号：US20100081665A1

  公开（公告）日：2010-04-01

  The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.

  本发明提供了三环化合物、芳香酰胺化合物和其他化合物以及包含它们的组合物，用于治疗疟疾，并且提供了通过将这些化合物用于动物的方法来治疗疟疾。
• CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF
  申请人：Chen Liang

  公开号：US20100113476A1

  公开（公告）日：2010-05-06

  The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体结合物，其具有强效的细胞毒性，并在药物和配体之间包含一个仅有一个氨基酸的连接物。本公开还涉及包含药物-配体结合物的组合物以及使用它们的治疗方法。